Hepatitis C: magnitude of the problem

Area of Science:

• Hepatology
• Transplantation Immunology
• Viral Hepatitis Research

Background:

• End-stage liver disease due to hepatitis C virus (HCV) infection is the primary indication for liver transplantation in the U.S.
• Comorbidities like alcoholism, steatosis, and viral coinfections can accelerate HCV-related liver disease progression.
• HCV progression to cirrhosis increases hepatocellular carcinoma risk, complicating patient management.

Purpose of the Study:

• To review the challenges and outcomes of liver transplantation in patients with end-stage liver disease caused by HCV.
• To identify risk factors affecting patient and graft survival post-transplantation.
• To highlight future research directions for managing HCV recurrence and optimizing antiviral therapies.

Main Methods:

• Literature review of studies on liver transplantation for HCV-related end-stage liver disease.
• Analysis of patient and graft survival data in HCV-positive versus HCV-negative transplant recipients.
• Identification and categorization of risk factors influencing post-transplant outcomes.

Main Results:

• Liver transplantation for HCV is associated with decreased patient and graft survival compared to other liver diseases.
• Host, viral, donor, and post-transplantation factors significantly impact outcomes.
• HCV recurrence post-transplantation is a major cause of graft dysfunction and failure.

Conclusions:

• HCV recurrence remains a significant challenge after liver transplantation, impacting long-term survival.
• Further research is crucial to define optimal antiviral strategies and manage retransplantation needs.
• Addressing comorbidities and understanding risk factors are key to improving outcomes for liver transplant recipients with HCV.